7月29日,默沙东公布2025H1业绩,上半年总营收313.35亿美元,同比下降2%。默沙东制药业务收入276.88亿美元,同比下降3%。其中,中国区收入同比下滑70%至10.75亿美元,占据默沙东全球制药业务3.9%的份额。值得注意的是,默沙东还在半年报公布之际宣布启动一项新的多年期优化计划,旨在通过生产力行动预计每年节省30亿美元的成本来实现其产品组合的转型,这些成本将全部再投资以支持新产品的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.